← FDA DRUG APPROVALS

FDA NDA · NDA020697

TASMAR

tolcapone

Sponsor: BAUSCH

APPLICATION
NDA020697
TYPE
NDA
ORIGINAL APPROVAL
1998-01-29
LATEST ACTION
2014-09-30
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription, Discontinued

Products

TASMAR · ReferencePrescription
TOLCAPONE 100MG · TABLET · ORAL
TASMARDiscontinued
TOLCAPONE 200MG · TABLET · ORAL

Approval history

2014-09-30Manufacturing (CMC) · Supplement 18 · standardAP
2013-05-11Labeling · Supplement 4 · standardLetterAP
2013-04-30Manufacturing (CMC) · Supplement 19 · standardAP
2009-06-30Manufacturing (CMC) · Supplement 16LetterAP
2009-02-09Labeling · Supplement 15 · standardLetterAP
2009-02-09Labeling · Supplement 13 · standardLabelAP
2007-01-24Labeling · Supplement 12 · standardLabelAP
2006-02-17Labeling · Supplement 10 · standardLabelAP
2001-01-24Manufacturing (CMC) · Supplement 6 · standardAP
2000-11-22Manufacturing (CMC) · Supplement 5 · standardAP
1998-11-16Labeling · Supplement 2 · standardAP
1998-04-24Manufacturing (CMC) · Supplement 1 · standardAP
1998-01-29Type 1 - New Molecular Entity · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →